Insider Selling: Artivion (NYSE:AORT) EVP Sells 4,981 Shares of Stock

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 4,981 shares of Artivion stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $37.59, for a total transaction of $187,235.79. Following the sale, the executive vice president owned 148,450 shares of the company’s stock, valued at approximately $5,580,235.50. The trade was a 3.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Artivion Stock Performance

Shares of Artivion stock traded up $0.31 during trading on Wednesday, hitting $35.66. 300,261 shares of the company’s stock were exchanged, compared to its average volume of 399,410. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The business has a 50-day simple moving average of $42.51 and a 200-day simple moving average of $43.14. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of 178.32 and a beta of 1.59.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. Artivion’s revenue was up 19.2% on a year-over-year basis. On average, research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Canaccord Genuity Group cut their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Needham & Company LLC restated a “buy” rating and issued a $58.00 price target on shares of Artivion in a research note on Monday, February 2nd. Finally, Citizens Jmp upped their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.97.

Hedge Funds Weigh In On Artivion

A number of hedge funds have recently made changes to their positions in AORT. Invesco Ltd. increased its holdings in shares of Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after buying an additional 748,119 shares during the last quarter. XTX Topco Ltd purchased a new position in Artivion in the fourth quarter worth approximately $746,000. Susquehanna Portfolio Strategies LLC increased its stake in Artivion by 21.5% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company’s stock worth $1,849,000 after acquiring an additional 7,186 shares during the last quarter. Occudo Quantitative Strategies LP purchased a new stake in Artivion in the fourth quarter valued at $248,000. Finally, Millennium Management LLC lifted its stake in shares of Artivion by 1.0% in the 4th quarter. Millennium Management LLC now owns 91,816 shares of the company’s stock valued at $4,188,000 after purchasing an additional 893 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.